TWI720946B - 包含改質套膜蛋白質ｅ３之類病毒粒子 - Google Patents
包含改質套膜蛋白質ｅ３之類病毒粒子 Download PDFInfo
- Publication number
- TWI720946B TWI720946B TW104125774A TW104125774A TWI720946B TW I720946 B TWI720946 B TW I720946B TW 104125774 A TW104125774 A TW 104125774A TW 104125774 A TW104125774 A TW 104125774A TW I720946 B TWI720946 B TW I720946B
- Authority
- TW
- Taiwan
- Prior art keywords
- virus
- antigen
- protein
- particles
- sequence
- Prior art date
Links
- 239000002245 particle Substances 0.000 title claims abstract description 294
- 241000700605 Viruses Species 0.000 title claims abstract description 208
- 101710091045 Envelope protein Proteins 0.000 title claims abstract description 38
- 101710188315 Protein X Proteins 0.000 title claims abstract description 38
- 102100021696 Syncytin-1 Human genes 0.000 title abstract 2
- 108010087302 Viral Structural Proteins Proteins 0.000 claims abstract description 150
- 241000710959 Venezuelan equine encephalitis virus Species 0.000 claims abstract description 149
- 241000710929 Alphavirus Species 0.000 claims abstract description 14
- 239000000427 antigen Substances 0.000 claims description 516
- 108091007433 antigens Proteins 0.000 claims description 515
- 102000036639 antigens Human genes 0.000 claims description 515
- 210000004027 cell Anatomy 0.000 claims description 106
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 104
- 201000004792 malaria Diseases 0.000 claims description 84
- 201000010099 disease Diseases 0.000 claims description 69
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 69
- 102000039446 nucleic acids Human genes 0.000 claims description 56
- 108020004707 nucleic acids Proteins 0.000 claims description 56
- 150000007523 nucleic acids Chemical class 0.000 claims description 56
- 101710089372 Programmed cell death protein 1 Proteins 0.000 claims description 54
- 102100040678 Programmed cell death protein 1 Human genes 0.000 claims description 54
- 101710132031 Mantle protein Proteins 0.000 claims description 49
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 46
- 102000008096 B7-H1 Antigen Human genes 0.000 claims description 46
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 46
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims description 38
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims description 38
- 239000013598 vector Substances 0.000 claims description 38
- 102100038132 Endogenous retrovirus group K member 6 Pro protein Human genes 0.000 claims description 37
- 238000004519 manufacturing process Methods 0.000 claims description 34
- 239000002773 nucleotide Substances 0.000 claims description 34
- 125000003729 nucleotide group Chemical group 0.000 claims description 34
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 31
- 102000008203 CTLA-4 Antigen Human genes 0.000 claims description 31
- 239000000203 mixture Substances 0.000 claims description 31
- 101000864344 Homo sapiens B- and T-lymphocyte attenuator Proteins 0.000 claims description 30
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 23
- 102100029822 B- and T-lymphocyte attenuator Human genes 0.000 claims description 22
- 102100022273 Disrupted in schizophrenia 1 protein Human genes 0.000 claims description 21
- 101000902072 Homo sapiens Disrupted in schizophrenia 1 protein Proteins 0.000 claims description 21
- 206010028980 Neoplasm Diseases 0.000 claims description 21
- 108010061593 Member 14 Tumor Necrosis Factor Receptors Proteins 0.000 claims description 20
- 102000012220 Member 14 Tumor Necrosis Factor Receptors Human genes 0.000 claims description 20
- 108010002350 Interleukin-2 Proteins 0.000 claims description 17
- 102000000588 Interleukin-2 Human genes 0.000 claims description 17
- 229960005486 vaccine Drugs 0.000 claims description 17
- 238000003776 cleavage reaction Methods 0.000 claims description 16
- 230000007017 scission Effects 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 108091005804 Peptidases Proteins 0.000 claims description 14
- 208000015181 infectious disease Diseases 0.000 claims description 13
- 239000004365 Protease Substances 0.000 claims description 12
- 230000035772 mutation Effects 0.000 claims description 11
- 241000124008 Mammalia Species 0.000 claims description 9
- 208000035473 Communicable disease Diseases 0.000 claims description 8
- 101710201734 E3 protein Proteins 0.000 claims description 8
- 208000012902 Nervous system disease Diseases 0.000 claims description 8
- 208000025966 Neurological disease Diseases 0.000 claims description 8
- 125000000539 amino acid group Chemical group 0.000 claims description 8
- 230000028993 immune response Effects 0.000 claims description 7
- 230000002265 prevention Effects 0.000 claims description 7
- 210000002540 macrophage Anatomy 0.000 claims description 6
- 101900205473 Plasmodium falciparum Circumsporozoite protein Proteins 0.000 claims description 5
- 230000008859 change Effects 0.000 claims description 5
- 239000003937 drug carrier Substances 0.000 claims description 4
- 108090001126 Furin Proteins 0.000 claims description 3
- 102000004961 Furin Human genes 0.000 claims description 3
- 230000003308 immunostimulating effect Effects 0.000 claims description 3
- 229940072690 valium Drugs 0.000 claims description 3
- 230000036039 immunity Effects 0.000 claims description 2
- 229940045513 CTLA4 antagonist Drugs 0.000 claims 1
- 108010052285 Membrane Proteins Proteins 0.000 claims 1
- 102000018697 Membrane Proteins Human genes 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 241000710831 Flavivirus Species 0.000 abstract description 9
- 241001502567 Chikungunya virus Species 0.000 abstract description 2
- 102100031675 DnaJ homolog subfamily C member 5 Human genes 0.000 description 69
- 238000000034 method Methods 0.000 description 65
- 101710172711 Structural protein Proteins 0.000 description 53
- 108020004414 DNA Proteins 0.000 description 50
- 108090000623 proteins and genes Proteins 0.000 description 46
- 102000004169 proteins and genes Human genes 0.000 description 44
- 235000018102 proteins Nutrition 0.000 description 43
- 210000002706 plastid Anatomy 0.000 description 38
- 239000013604 expression vector Substances 0.000 description 31
- 238000001262 western blot Methods 0.000 description 29
- 241000699670 Mus sp. Species 0.000 description 28
- 239000012634 fragment Substances 0.000 description 27
- 108020004705 Codon Proteins 0.000 description 23
- 108091026890 Coding region Proteins 0.000 description 22
- 108091033319 polynucleotide Proteins 0.000 description 22
- 102000040430 polynucleotide Human genes 0.000 description 22
- 239000002157 polynucleotide Substances 0.000 description 22
- 241000699666 Mus <mouse, genus> Species 0.000 description 21
- 230000003053 immunization Effects 0.000 description 20
- 238000002649 immunization Methods 0.000 description 20
- 229920001184 polypeptide Polymers 0.000 description 19
- 238000002360 preparation method Methods 0.000 description 19
- 239000006228 supernatant Substances 0.000 description 18
- 101710117490 Circumsporozoite protein Proteins 0.000 description 17
- 241000223960 Plasmodium falciparum Species 0.000 description 17
- 235000001014 amino acid Nutrition 0.000 description 17
- 150000001413 amino acids Chemical class 0.000 description 17
- 210000000234 capsid Anatomy 0.000 description 17
- 101001098868 Homo sapiens Proprotein convertase subtilisin/kexin type 9 Proteins 0.000 description 14
- 102100038955 Proprotein convertase subtilisin/kexin type 9 Human genes 0.000 description 14
- 102000035195 Peptidases Human genes 0.000 description 13
- 241000223830 Plasmodium yoelii Species 0.000 description 12
- 241001465754 Metazoa Species 0.000 description 11
- 210000004899 c-terminal region Anatomy 0.000 description 11
- 108020001507 fusion proteins Proteins 0.000 description 11
- 102000037865 fusion proteins Human genes 0.000 description 11
- 238000003780 insertion Methods 0.000 description 11
- 230000037431 insertion Effects 0.000 description 11
- 239000003446 ligand Substances 0.000 description 11
- 238000001890 transfection Methods 0.000 description 11
- 108010013369 Enteropeptidase Proteins 0.000 description 10
- 102100029727 Enteropeptidase Human genes 0.000 description 10
- 108010074860 Factor Xa Proteins 0.000 description 10
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 9
- 101001043827 Mus musculus Interleukin-2 Proteins 0.000 description 9
- 235000019419 proteases Nutrition 0.000 description 9
- 230000003612 virological effect Effects 0.000 description 9
- 108090000565 Capsid Proteins Proteins 0.000 description 8
- 101710185720 Putative ethidium bromide resistance protein Proteins 0.000 description 8
- 230000009977 dual effect Effects 0.000 description 8
- 102000053464 human BTLA Human genes 0.000 description 8
- 108091005573 modified proteins Proteins 0.000 description 8
- 102000035118 modified proteins Human genes 0.000 description 8
- 210000002966 serum Anatomy 0.000 description 8
- 101100519207 Mus musculus Pdcd1 gene Proteins 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 7
- 239000003636 conditioned culture medium Substances 0.000 description 7
- 238000002965 ELISA Methods 0.000 description 6
- 101001117316 Mus musculus Programmed cell death 1 ligand 1 Proteins 0.000 description 6
- 210000003719 b-lymphocyte Anatomy 0.000 description 6
- 101800001643 6K protein Proteins 0.000 description 5
- 101710125507 Integrase/recombinase Proteins 0.000 description 5
- 101100407308 Mus musculus Pdcd1lg2 gene Proteins 0.000 description 5
- 108700030875 Programmed Cell Death 1 Ligand 2 Proteins 0.000 description 5
- 102100024213 Programmed cell death 1 ligand 2 Human genes 0.000 description 5
- 210000004962 mammalian cell Anatomy 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 206010014611 Encephalitis venezuelan equine Diseases 0.000 description 4
- 241000700721 Hepatitis B virus Species 0.000 description 4
- 241000282412 Homo Species 0.000 description 4
- 108091028043 Nucleic acid sequence Proteins 0.000 description 4
- 241000224016 Plasmodium Species 0.000 description 4
- 108700011066 PreScission Protease Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 208000002687 Venezuelan Equine Encephalomyelitis Diseases 0.000 description 4
- 201000009145 Venezuelan equine encephalitis Diseases 0.000 description 4
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 4
- 229910052782 aluminium Inorganic materials 0.000 description 4
- 150000001412 amines Chemical class 0.000 description 4
- 238000012258 culturing Methods 0.000 description 4
- 230000002708 enhancing effect Effects 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 230000000638 stimulation Effects 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 210000000605 viral structure Anatomy 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 125000001433 C-terminal amino-acid group Chemical group 0.000 description 3
- -1 CTLA -4 Proteins 0.000 description 3
- 102100023321 Ceruloplasmin Human genes 0.000 description 3
- 102000005593 Endopeptidases Human genes 0.000 description 3
- 108010059378 Endopeptidases Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- 108060003951 Immunoglobulin Proteins 0.000 description 3
- 102220536254 Keratin-associated protein 10-2_D34K_mutation Human genes 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 125000000729 N-terminal amino-acid group Chemical group 0.000 description 3
- 102220567148 Ornithine decarboxylase antizyme 1_F54M_mutation Human genes 0.000 description 3
- 241000223810 Plasmodium vivax Species 0.000 description 3
- 108010076504 Protein Sorting Signals Proteins 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 230000000890 antigenic effect Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 3
- 239000003292 glue Substances 0.000 description 3
- 102000018358 immunoglobulin Human genes 0.000 description 3
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 108010087967 type I signal peptidase Proteins 0.000 description 3
- 241000712461 unidentified influenza virus Species 0.000 description 3
- NQUNIMFHIWQQGJ-UHFFFAOYSA-N 2-nitro-5-thiocyanatobenzoic acid Chemical compound OC(=O)C1=CC(SC#N)=CC=C1[N+]([O-])=O NQUNIMFHIWQQGJ-UHFFFAOYSA-N 0.000 description 2
- 208000006400 Arbovirus Encephalitis Diseases 0.000 description 2
- YNCHFVRXEQFPBY-BQBZGAKWSA-N Asp-Gly-Arg Chemical compound OC(=O)C[C@H](N)C(=O)NCC(=O)N[C@H](C(O)=O)CCCN=C(N)N YNCHFVRXEQFPBY-BQBZGAKWSA-N 0.000 description 2
- 241000711404 Avian avulavirus 1 Species 0.000 description 2
- 241000710946 Barmah Forest virus Species 0.000 description 2
- 241000120506 Bluetongue virus Species 0.000 description 2
- 241000282693 Cercopithecidae Species 0.000 description 2
- 208000017667 Chronic Disease Diseases 0.000 description 2
- 241000223205 Coccidioides immitis Species 0.000 description 2
- 239000004971 Cross linker Substances 0.000 description 2
- 108010041986 DNA Vaccines Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 241000725619 Dengue virus Species 0.000 description 2
- 241000702421 Dependoparvovirus Species 0.000 description 2
- 241000224432 Entamoeba histolytica Species 0.000 description 2
- 206010066919 Epidemic polyarthritis Diseases 0.000 description 2
- YQYJSBFKSSDGFO-UHFFFAOYSA-N Epihygromycin Natural products OC1C(O)C(C(=O)C)OC1OC(C(=C1)O)=CC=C1C=C(C)C(=O)NC1C(O)C(O)C2OCOC2C1O YQYJSBFKSSDGFO-UHFFFAOYSA-N 0.000 description 2
- 208000000832 Equine Encephalomyelitis Diseases 0.000 description 2
- 241000283073 Equus caballus Species 0.000 description 2
- 241000588724 Escherichia coli Species 0.000 description 2
- 241000224466 Giardia Species 0.000 description 2
- 108060005986 Granzyme Proteins 0.000 description 2
- 102000001398 Granzyme Human genes 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 241000724675 Hepatitis E virus Species 0.000 description 2
- 241000724709 Hepatitis delta virus Species 0.000 description 2
- 241000228404 Histoplasma capsulatum Species 0.000 description 2
- 241000701806 Human papillomavirus Species 0.000 description 2
- GRRNUXAQVGOGFE-UHFFFAOYSA-N Hygromycin-B Natural products OC1C(NC)CC(N)C(O)C1OC1C2OC3(C(C(O)C(O)C(C(N)CO)O3)O)OC2C(O)C(CO)O1 GRRNUXAQVGOGFE-UHFFFAOYSA-N 0.000 description 2
- KTGFOCFYOZQVRJ-ZKWXMUAHSA-N Ile-Glu Chemical compound CC[C@H](C)[C@H](N)C(=O)N[C@H](C(O)=O)CCC(O)=O KTGFOCFYOZQVRJ-ZKWXMUAHSA-N 0.000 description 2
- 241000701460 JC polyomavirus Species 0.000 description 2
- 208000008839 Kidney Neoplasms Diseases 0.000 description 2
- 206010024238 Leptospirosis Diseases 0.000 description 2
- 208000016604 Lyme disease Diseases 0.000 description 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 2
- 241000235395 Mucor Species 0.000 description 2
- 101100058686 Mus musculus Btla gene Proteins 0.000 description 2
- 101100407306 Mus musculus Cd274 gene Proteins 0.000 description 2
- 101100508544 Mus musculus Il2 gene Proteins 0.000 description 2
- 241000224017 Plasmodium berghei Species 0.000 description 2
- 241000224024 Plasmodium chabaudi Species 0.000 description 2
- 241000223801 Plasmodium knowlesi Species 0.000 description 2
- 241001505293 Plasmodium ovale Species 0.000 description 2
- 241000702619 Porcine parvovirus Species 0.000 description 2
- 241000125945 Protoparvovirus Species 0.000 description 2
- 241000714203 Rabbit hemorrhagic disease virus Species 0.000 description 2
- 241000710942 Ross River virus Species 0.000 description 2
- 241000702670 Rotavirus Species 0.000 description 2
- 241001660014 Salmon pancreas disease virus Species 0.000 description 2
- 241000710961 Semliki Forest virus Species 0.000 description 2
- 241000713311 Simian immunodeficiency virus Species 0.000 description 2
- 241000710960 Sindbis virus Species 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 241000709710 Swine vesicular disease virus Species 0.000 description 2
- 108091008874 T cell receptors Proteins 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- 108090001109 Thermolysin Proteins 0.000 description 2
- 241000223996 Toxoplasma Species 0.000 description 2
- 241000746998 Tragus Species 0.000 description 2
- 206010046458 Urethral neoplasms Diseases 0.000 description 2
- 241000710951 Western equine encephalitis virus Species 0.000 description 2
- 230000004075 alteration Effects 0.000 description 2
- 125000003277 amino group Chemical group 0.000 description 2
- 230000001640 apoptogenic effect Effects 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 2
- 108090001092 clostripain Proteins 0.000 description 2
- 239000002131 composite material Substances 0.000 description 2
- 239000012228 culture supernatant Substances 0.000 description 2
- 229940007078 entamoeba histolytica Drugs 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 208000014829 head and neck neoplasm Diseases 0.000 description 2
- GRRNUXAQVGOGFE-NZSRVPFOSA-N hygromycin B Chemical compound O[C@@H]1[C@@H](NC)C[C@@H](N)[C@H](O)[C@H]1O[C@H]1[C@H]2O[C@@]3([C@@H]([C@@H](O)[C@@H](O)[C@@H](C(N)CO)O3)O)O[C@H]2[C@@H](O)[C@@H](CO)O1 GRRNUXAQVGOGFE-NZSRVPFOSA-N 0.000 description 2
- 229940097277 hygromycin b Drugs 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 238000007912 intraperitoneal administration Methods 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 201000001441 melanoma Diseases 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 235000019833 protease Nutrition 0.000 description 2
- 201000000980 schizophrenia Diseases 0.000 description 2
- 239000006152 selective media Substances 0.000 description 2
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 206010041823 squamous cell carcinoma Diseases 0.000 description 2
- 238000007920 subcutaneous administration Methods 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 125000003396 thiol group Chemical group [H]S* 0.000 description 2
- 238000003146 transient transfection Methods 0.000 description 2
- 108010060175 trypsinogen activation peptide Proteins 0.000 description 2
- 229940125575 vaccine candidate Drugs 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 210000005253 yeast cell Anatomy 0.000 description 2
- WCMOHMXWOOBVMZ-UHFFFAOYSA-N (2,5-dioxopyrrolidin-1-yl) 6-[3-(2,5-dioxopyrrol-1-yl)propanoylamino]hexanoate Chemical compound O=C1CCC(=O)N1OC(=O)CCCCCNC(=O)CCN1C(=O)C=CC1=O WCMOHMXWOOBVMZ-UHFFFAOYSA-N 0.000 description 1
- DIYPCWKHSODVAP-UHFFFAOYSA-N 1-[3-(2,5-dioxopyrrol-1-yl)benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=CC(N2C(C=CC2=O)=O)=C1 DIYPCWKHSODVAP-UHFFFAOYSA-N 0.000 description 1
- CULQNACJHGHAER-UHFFFAOYSA-N 1-[4-[(2-iodoacetyl)amino]benzoyl]oxy-2,5-dioxopyrrolidine-3-sulfonic acid Chemical compound O=C1C(S(=O)(=O)O)CC(=O)N1OC(=O)C1=CC=C(NC(=O)CI)C=C1 CULQNACJHGHAER-UHFFFAOYSA-N 0.000 description 1
- ZCNXIMPBRKMUGC-UHFFFAOYSA-N 2-iodosylbenzoic acid Chemical compound I(=O)C1=C(C(=O)O)C=CC=C1.I(=O)C1=C(C(=O)O)C=CC=C1 ZCNXIMPBRKMUGC-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 241000235389 Absidia Species 0.000 description 1
- OPVPGKGADVGKTG-BQBZGAKWSA-N Ac-Asp-Glu Chemical compound CC(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(O)=O)CCC(O)=O OPVPGKGADVGKTG-BQBZGAKWSA-N 0.000 description 1
- 241000224424 Acanthamoeba sp. Species 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 206010000830 Acute leukaemia Diseases 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 241000272814 Anser sp. Species 0.000 description 1
- 208000007860 Anus Neoplasms Diseases 0.000 description 1
- 235000017060 Arachis glabrata Nutrition 0.000 description 1
- 244000105624 Arachis hypogaea Species 0.000 description 1
- 235000010777 Arachis hypogaea Nutrition 0.000 description 1
- 235000018262 Arachis monticola Nutrition 0.000 description 1
- 241000228212 Aspergillus Species 0.000 description 1
- 241000178568 Aura virus Species 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000271566 Aves Species 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 238000011725 BALB/c mouse Methods 0.000 description 1
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 description 1
- BXTVQNYQYUTQAZ-UHFFFAOYSA-N BNPS-skatole Chemical group N=1C2=CC=CC=C2C(C)(Br)C=1SC1=CC=CC=C1[N+]([O-])=O BXTVQNYQYUTQAZ-UHFFFAOYSA-N 0.000 description 1
- 241000231314 Babanki virus Species 0.000 description 1
- 241000223848 Babesia microti Species 0.000 description 1
- 241000304886 Bacilli Species 0.000 description 1
- 241000193738 Bacillus anthracis Species 0.000 description 1
- 241001235572 Balantioides coli Species 0.000 description 1
- 241001302800 Beak and feather disease virus Species 0.000 description 1
- 241000608319 Bebaru virus Species 0.000 description 1
- 241000228405 Blastomyces dermatitidis Species 0.000 description 1
- 206010005949 Bone cancer Diseases 0.000 description 1
- 208000018084 Bone neoplasm Diseases 0.000 description 1
- 208000003508 Botulism Diseases 0.000 description 1
- 206010006143 Brain stem glioma Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000027312 Bursal disease Diseases 0.000 description 1
- 241000868138 Cabassou virus Species 0.000 description 1
- 241000282832 Camelidae Species 0.000 description 1
- 241000222120 Candida <Saccharomycetales> Species 0.000 description 1
- 241000222178 Candida tropicalis Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 108010076667 Caspases Proteins 0.000 description 1
- 102000011727 Caspases Human genes 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 229940124957 Cervarix Drugs 0.000 description 1
- 241000606161 Chlamydia Species 0.000 description 1
- 206010008631 Cholera Diseases 0.000 description 1
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 description 1
- 108090000317 Chymotrypsin Proteins 0.000 description 1
- 241000223782 Ciliophora Species 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 241000709687 Coxsackievirus Species 0.000 description 1
- 201000007336 Cryptococcosis Diseases 0.000 description 1
- 241000221204 Cryptococcus neoformans Species 0.000 description 1
- 241000295636 Cryptosporidium sp. Species 0.000 description 1
- 229940126190 DNA methyltransferase inhibitor Drugs 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 201000011001 Ebola Hemorrhagic Fever Diseases 0.000 description 1
- 241001115402 Ebolavirus Species 0.000 description 1
- 241001466953 Echovirus Species 0.000 description 1
- 241000353621 Eilat virus Species 0.000 description 1
- 108010067770 Endopeptidase K Proteins 0.000 description 1
- 241000709661 Enterovirus Species 0.000 description 1
- 241001529459 Enterovirus A71 Species 0.000 description 1
- 241000991587 Enterovirus C Species 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000701959 Escherichia virus Lambda Species 0.000 description 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 1
- 241000465885 Everglades virus Species 0.000 description 1
- 201000001342 Fallopian tube cancer Diseases 0.000 description 1
- 241000231322 Fort Morgan virus Species 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 229940124897 Gardasil Drugs 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 241000608297 Getah virus Species 0.000 description 1
- 241000252870 H3N2 subtype Species 0.000 description 1
- 208000037262 Hepatitis delta Diseases 0.000 description 1
- 241000710948 Highlands J virus Species 0.000 description 1
- 108010033040 Histones Proteins 0.000 description 1
- 208000017604 Hodgkin disease Diseases 0.000 description 1
- 208000010747 Hodgkins lymphoma Diseases 0.000 description 1
- 101000889276 Homo sapiens Cytotoxic T-lymphocyte protein 4 Proteins 0.000 description 1
- 101001117317 Homo sapiens Programmed cell death 1 ligand 1 Proteins 0.000 description 1
- 101001117312 Homo sapiens Programmed cell death 1 ligand 2 Proteins 0.000 description 1
- 101000611936 Homo sapiens Programmed cell death protein 1 Proteins 0.000 description 1
- 101000648507 Homo sapiens Tumor necrosis factor receptor superfamily member 14 Proteins 0.000 description 1
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 1
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 1
- 241001500351 Influenzavirus A Species 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 241000588748 Klebsiella Species 0.000 description 1
- 241000231318 Kyzylagach virus Species 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- 125000003338 L-glutaminyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C([H])([H])C(=O)N([H])[H] 0.000 description 1
- 241001313288 Labia Species 0.000 description 1
- 241001245510 Lambia <signal fly> Species 0.000 description 1
- 241000589248 Legionella Species 0.000 description 1
- 208000007764 Legionnaires' Disease Diseases 0.000 description 1
- 241000222722 Leishmania <genus> Species 0.000 description 1
- 241000222727 Leishmania donovani Species 0.000 description 1
- 108010028275 Leukocyte Elastase Proteins 0.000 description 1
- 102000016799 Leukocyte elastase Human genes 0.000 description 1
- 206010052178 Lymphocytic lymphoma Diseases 0.000 description 1
- 101000667310 Macrovipera lebetina Venom serine proteinase-like protein 2 Proteins 0.000 description 1
- 241001115401 Marburgvirus Species 0.000 description 1
- 241000608292 Mayaro virus Species 0.000 description 1
- 241000763097 Me Tri virus Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241000710949 Middelburg virus Species 0.000 description 1
- 241000283127 Mirounga leonina Species 0.000 description 1
- 241000465889 Mosso das Pedras virus Species 0.000 description 1
- 241000868135 Mucambo virus Species 0.000 description 1
- 241000235388 Mucorales Species 0.000 description 1
- 241000711386 Mumps virus Species 0.000 description 1
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 241000224438 Naegleria fowleri Species 0.000 description 1
- 241000608287 Ndumu virus Species 0.000 description 1
- 241001126259 Nippostrongylus brasiliensis Species 0.000 description 1
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 description 1
- 241001263478 Norovirus Species 0.000 description 1
- 241000714209 Norwalk virus Species 0.000 description 1
- 241000710944 O'nyong-nyong virus Species 0.000 description 1
- 108091034117 Oligonucleotide Proteins 0.000 description 1
- 102220567164 Ornithine decarboxylase antizyme 1_K64A_mutation Human genes 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 201000010183 Papilledema Diseases 0.000 description 1
- 206010033708 Papillitis Diseases 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 241000526686 Paracoccidioides brasiliensis Species 0.000 description 1
- 208000000821 Parathyroid Neoplasms Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 208000002471 Penile Neoplasms Diseases 0.000 description 1
- 102000057297 Pepsin A Human genes 0.000 description 1
- 108090000284 Pepsin A Proteins 0.000 description 1
- 244000064622 Physalis edulis Species 0.000 description 1
- 241000233614 Phytophthora Species 0.000 description 1
- 208000007913 Pituitary Neoplasms Diseases 0.000 description 1
- 241000868134 Pixuna virus Species 0.000 description 1
- 206010035148 Plague Diseases 0.000 description 1
- 241000223821 Plasmodium malariae Species 0.000 description 1
- 101000726024 Plasmodium malariae Circumsporozoite protein Proteins 0.000 description 1
- 206010035501 Plasmodium malariae infection Diseases 0.000 description 1
- 206010035502 Plasmodium ovale infection Diseases 0.000 description 1
- 101900284417 Plasmodium vivax Circumsporozoite protein Proteins 0.000 description 1
- 206010035503 Plasmodium vivax infection Diseases 0.000 description 1
- 241000233872 Pneumocystis carinii Species 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- 102100034014 Prolyl 3-hydroxylase 3 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 101710132611 Protein E3 Proteins 0.000 description 1
- 241000588769 Proteus <enterobacteria> Species 0.000 description 1
- 241000589516 Pseudomonas Species 0.000 description 1
- 101100084022 Pseudomonas aeruginosa (strain ATCC 15692 / DSM 22644 / CIP 104116 / JCM 14847 / LMG 12228 / 1C / PRS 101 / PAO1) lapA gene Proteins 0.000 description 1
- 241000287531 Psittacidae Species 0.000 description 1
- 241000219492 Quercus Species 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 229940124942 Recombivax HB Drugs 0.000 description 1
- 108700033496 Recombivax HB Proteins 0.000 description 1
- 208000015634 Rectal Neoplasms Diseases 0.000 description 1
- 206010038389 Renal cancer Diseases 0.000 description 1
- 241000725643 Respiratory syncytial virus Species 0.000 description 1
- 241000606651 Rickettsiales Species 0.000 description 1
- 241000328499 Rio Negro virus Species 0.000 description 1
- 241000710799 Rubella virus Species 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000607720 Serratia Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 1
- 241001472492 Southern elephant seal virus Species 0.000 description 1
- 241001149962 Sporothrix Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 102100033130 T-box transcription factor T Human genes 0.000 description 1
- 206010042971 T-cell lymphoma Diseases 0.000 description 1
- 208000027585 T-cell non-Hodgkin lymphoma Diseases 0.000 description 1
- 108010076818 TEV protease Proteins 0.000 description 1
- 208000024313 Testicular Neoplasms Diseases 0.000 description 1
- 206010057644 Testis cancer Diseases 0.000 description 1
- 206010043376 Tetanus Diseases 0.000 description 1
- 108090000190 Thrombin Proteins 0.000 description 1
- 208000024770 Thyroid neoplasm Diseases 0.000 description 1
- 241000710771 Tick-borne encephalitis virus Species 0.000 description 1
- 241000868137 Tonate virus Species 0.000 description 1
- 206010044668 Trigonitis Diseases 0.000 description 1
- 241000951300 Trocara virus Species 0.000 description 1
- 241000223105 Trypanosoma brucei Species 0.000 description 1
- 241000223109 Trypanosoma cruzi Species 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 241000608278 Una virus Species 0.000 description 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
- 208000002495 Uterine Neoplasms Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 241000607626 Vibrio cholerae Species 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 241000726445 Viroids Species 0.000 description 1
- 241000710886 West Nile virus Species 0.000 description 1
- 241000231320 Whataroa virus Species 0.000 description 1
- 241000710772 Yellow fever virus Species 0.000 description 1
- 241000607479 Yersinia pestis Species 0.000 description 1
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 241000222126 [Candida] glabrata Species 0.000 description 1
- 208000024447 adrenal gland neoplasm Diseases 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 201000011165 anus cancer Diseases 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000010425 asbestos Substances 0.000 description 1
- 208000007456 balantidiasis Diseases 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 208000032343 candida glabrata infection Diseases 0.000 description 1
- 208000025997 central nervous system neoplasm Diseases 0.000 description 1
- 201000010881 cervical cancer Diseases 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 208000024207 chronic leukemia Diseases 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 229960002376 chymotrypsin Drugs 0.000 description 1
- 150000001875 compounds Chemical group 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 208000035250 cutaneous malignant susceptibility to 1 melanoma Diseases 0.000 description 1
- ATDGTVJJHBUTRL-UHFFFAOYSA-N cyanogen bromide Chemical compound BrC#N ATDGTVJJHBUTRL-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 206010013023 diphtheria Diseases 0.000 description 1
- LVXHNCUCBXIIPE-UHFFFAOYSA-L disodium;hydrogen phosphate;hydrate Chemical compound O.[Na+].[Na+].OP([O-])([O-])=O LVXHNCUCBXIIPE-UHFFFAOYSA-L 0.000 description 1
- 239000003968 dna methyltransferase inhibitor Substances 0.000 description 1
- 238000009509 drug development Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 210000000750 endocrine system Anatomy 0.000 description 1
- 210000004696 endometrium Anatomy 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- 201000004101 esophageal cancer Diseases 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 230000002008 hemorrhagic effect Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 208000029570 hepatitis D virus infection Diseases 0.000 description 1
- 102000048776 human CD274 Human genes 0.000 description 1
- 102000043321 human CTLA4 Human genes 0.000 description 1
- 102000048362 human PDCD1 Human genes 0.000 description 1
- 102000048119 human PDCD1LG2 Human genes 0.000 description 1
- 102000052793 human TNFRSF14 Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 229960001438 immunostimulant agent Drugs 0.000 description 1
- 239000003022 immunostimulating agent Substances 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 201000010982 kidney cancer Diseases 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 238000001638 lipofection Methods 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 208000020984 malignant renal pelvis neoplasm Diseases 0.000 description 1
- 208000026037 malignant tumor of neck Diseases 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 108091005601 modified peptides Proteins 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000001613 neoplastic effect Effects 0.000 description 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 description 1
- 201000002166 optic papillitis Diseases 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229960005030 other vaccine in atc Drugs 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 235000020232 peanut Nutrition 0.000 description 1
- 229940111202 pepsin Drugs 0.000 description 1
- 101150009573 phoA gene Proteins 0.000 description 1
- 230000004962 physiological condition Effects 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 230000037452 priming Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 206010038038 rectal cancer Diseases 0.000 description 1
- 201000001275 rectum cancer Diseases 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000003252 repetitive effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 229910052895 riebeckite Inorganic materials 0.000 description 1
- 102220049431 rs587784257 Human genes 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- ULARYIUTHAWJMU-UHFFFAOYSA-M sodium;1-[4-(2,5-dioxopyrrol-1-yl)butanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCN1C(=O)C=CC1=O ULARYIUTHAWJMU-UHFFFAOYSA-M 0.000 description 1
- VUFNRPJNRFOTGK-UHFFFAOYSA-M sodium;1-[4-[(2,5-dioxopyrrol-1-yl)methyl]cyclohexanecarbonyl]oxy-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)C1CCC(CN2C(C=CC2=O)=O)CC1 VUFNRPJNRFOTGK-UHFFFAOYSA-M 0.000 description 1
- MIDXXTLMKGZDPV-UHFFFAOYSA-M sodium;1-[6-(2,5-dioxopyrrol-1-yl)hexanoyloxy]-2,5-dioxopyrrolidine-3-sulfonate Chemical compound [Na+].O=C1C(S(=O)(=O)[O-])CC(=O)N1OC(=O)CCCCCN1C(=O)C=CC1=O MIDXXTLMKGZDPV-UHFFFAOYSA-M 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000278 spinal cord Anatomy 0.000 description 1
- 210000003046 sporozoite Anatomy 0.000 description 1
- 238000007447 staining method Methods 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 201000003120 testicular cancer Diseases 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 229960004072 thrombin Drugs 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 241000701447 unidentified baculovirus Species 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 210000003708 urethra Anatomy 0.000 description 1
- 206010046766 uterine cancer Diseases 0.000 description 1
- 206010046885 vaginal cancer Diseases 0.000 description 1
- 229940118696 vibrio cholerae Drugs 0.000 description 1
- 229940051021 yellow-fever virus Drugs 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/002—Protozoa antigens
- A61K39/015—Hemosporidia antigens, e.g. Plasmodium antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36123—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Microbiology (AREA)
- Organic Chemistry (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (10)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462035037P | 2014-08-08 | 2014-08-08 | |
| US62/035,037 | 2014-08-08 | ||
| US201462079128P | 2014-11-13 | 2014-11-13 | |
| US62/079,128 | 2014-11-13 | ||
| US201562101514P | 2015-01-09 | 2015-01-09 | |
| US62/101,514 | 2015-01-09 | ||
| US201562120569P | 2015-02-25 | 2015-02-25 | |
| US62/120,569 | 2015-02-25 | ||
| US201562198949P | 2015-07-30 | 2015-07-30 | |
| US62/198,949 | 2015-07-30 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW201614067A TW201614067A (en) | 2016-04-16 |
| TWI720946B true TWI720946B (zh) | 2021-03-11 |
Family
ID=55263499
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW104125774A TWI720946B (zh) | 2014-08-08 | 2015-08-07 | 包含改質套膜蛋白質ｅ３之類病毒粒子 |
Country Status (6)
| Country | Link |
|---|---|
| US (1) | US9969986B2 (OSRAM) |
| EP (1) | EP3177720B1 (OSRAM) |
| JP (1) | JP6824154B2 (OSRAM) |
| CN (1) | CN106795513B (OSRAM) |
| TW (1) | TWI720946B (OSRAM) |
| WO (1) | WO2016021209A1 (OSRAM) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2013221187B9 (en) | 2012-02-16 | 2018-01-04 | Vlp Therapeutics, Inc. | Virus like particle composition |
| AU2014275772B2 (en) | 2013-06-03 | 2020-01-02 | Vlp Therapeutics, Inc. | Malaria vaccine |
| US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
| CN105792842B (zh) | 2013-10-11 | 2020-06-02 | 美利坚合众国, 由健康及人类服务部部长代表 | 埃巴病毒疫苗 |
| JP6824154B2 (ja) | 2014-08-08 | 2021-02-03 | ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ | 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子 |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| WO2016038895A1 (en) | 2014-09-11 | 2016-03-17 | Vlp Therapeutics, Llc | Flavivirus virus like particle |
| SG11201705264WA (en) | 2014-12-31 | 2017-07-28 | The Usa As Represented By The Secretary Detp Of Health And Human Services | Novel multivalent nanoparticle-based vaccines |
| US10166281B2 (en) | 2015-09-04 | 2019-01-01 | Vlp Therapeutics, Llc | Method and composition for modulating immune response |
| WO2017150683A1 (en) * | 2016-03-04 | 2017-09-08 | Vlp Therapeutics, Llc | Zika virus virus like particle |
| US11020473B2 (en) * | 2016-06-24 | 2021-06-01 | Institut Pasteur | Compositions and methods comprising measles virus defective interfering particles for the prevention of infectious diseases |
| IL265121B2 (en) | 2016-09-02 | 2023-11-01 | Us Health | Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof |
| EP3600406A4 (en) | 2017-03-28 | 2021-01-13 | Children's Hospital Medical Center | BIVALENT VLP VACCINES AGAINST EBOLA VIRUS AND THEIR MANUFACTURING AND USE PROCEDURES |
| BR112019020386A2 (pt) * | 2017-03-28 | 2020-06-09 | Mayo Found Medical Education & Res | vacinas de peptídeos de pd-1 humana e usos das mesmas |
| EP3728611A4 (en) | 2017-12-20 | 2021-09-08 | VLP Therapeutics, Inc. | ALPHAVIRUS REPLICON PARTICLE |
| CN112203681B (zh) * | 2018-02-07 | 2024-05-24 | 免疫基因有限公司 | 疫苗组合物及其用途 |
| JP7359390B2 (ja) | 2018-02-09 | 2023-10-11 | 国立大学法人大阪大学 | チクングニアウイルスに対する抗体またはその抗原結合断片、およびその用途 |
| FR3078535B1 (fr) * | 2018-03-05 | 2024-02-09 | Peptinov Sas | Composition vaccinale anti-pd-l1 |
| FR3078536A1 (fr) * | 2018-03-05 | 2019-09-06 | Peptinov Sas | Composition vaccinale anti-pd-1 |
| CN109536464B (zh) * | 2018-12-10 | 2022-06-10 | 中国科学院武汉病毒研究所 | 一种缺失衣壳蛋白基因的基孔肯雅病毒感染性克隆及构建方法和在制备减毒疫苗中的应用 |
| JP7644993B2 (ja) | 2020-04-17 | 2025-03-13 | ブイエルピー・セラピューティクス・インコーポレイテッド | コロナウイルスワクチン |
| IL297564A (en) | 2020-04-30 | 2022-12-01 | Vlp Therapeutics Inc | Cytokine immunotherapy |
| US20220347261A1 (en) * | 2021-04-23 | 2022-11-03 | Vlp Therapeutics, Inc. | Galectin-targeting immunotherapy |
| CN115466330B (zh) * | 2021-06-10 | 2023-10-20 | 清华大学 | 一种基于病毒样颗粒呈递冠状病毒受体结合区的冠状病毒亚单位疫苗 |
| WO2023204148A1 (en) * | 2022-04-18 | 2023-10-26 | Cyn-K, Llc | Treatment of inflammatory conditions |
| CN116042657A (zh) * | 2023-01-16 | 2023-05-02 | 上海复诺健生物科技有限公司 | 自复制信使核糖核酸疫苗 |
| WO2025084276A1 (ja) * | 2023-10-16 | 2025-04-24 | Ｃｙｎ－Ｋバイオ株式会社 | 肥満の処置 |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201345926A (zh) * | 2012-02-16 | 2013-11-16 | Vlp Therapeutics Llc | 類似病毒粒子組成物 |
Family Cites Families (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8923123D0 (en) | 1989-10-13 | 1989-11-29 | Connaught Lab | A vaccine for human immunodeficiency virus |
| DE69133566T2 (de) | 1990-01-12 | 2007-12-06 | Amgen Fremont Inc. | Bildung von xenogenen Antikörpern |
| AU2927892A (en) | 1991-11-16 | 1993-06-15 | Smithkline Beecham Biologicals (Sa) | Hybrid protein between cs from plasmodium and hbsag |
| US5580773A (en) | 1992-06-17 | 1996-12-03 | Korea Green Cross Corporation | Chimeric immunogenic gag-V3 virus-like particles of the human immunodeficiency virus (HIV) |
| CA2143491C (en) | 1994-03-01 | 2011-02-22 | Yasumasa Ishida | A novel peptide related to human programmed cell death and dna encoding it |
| WO1997012048A1 (en) | 1995-09-27 | 1997-04-03 | Medical Research Council | Recombinant viruses incorporating a protease cleavable protein |
| JP2002507393A (ja) | 1998-02-11 | 2002-03-12 | マキシジェン， インコーポレイテッド | 抗原ライブラリー免疫 |
| EP1210428B1 (en) | 1999-08-23 | 2015-03-18 | Dana-Farber Cancer Institute, Inc. | Pd-1, a receptor for b7-4, and uses therefor |
| CA2448908C (en) | 2001-05-30 | 2008-03-18 | Transgene S.A. | Adenovirus protein ix, its domains involved in capsid assembly, transcriptional activity and nuclear reorganization |
| AU2003281200A1 (en) | 2002-07-03 | 2004-01-23 | Tasuku Honjo | Immunopotentiating compositions |
| WO2004043399A2 (en) | 2002-11-13 | 2004-05-27 | The United States Of America As Represented By The Secretary Of The Navy | Methods and compositions for inducing immune responses and protective immunity by priming with alphavirus replicon vaccines |
| WO2005000881A2 (en) * | 2003-05-29 | 2005-01-06 | United States Army Medical Research Institute For Infectious Diseases | Live attenuated viral vaccines for eastern equine encephalitis virus |
| JP2007512842A (ja) | 2003-12-01 | 2007-05-24 | ダウ グローバル テクノロジーズ インコーポレイティド | シュードモナスにおける組換え二十面体ウイルス様粒子の生産 |
| EA016648B1 (ru) | 2004-10-14 | 2012-06-29 | Круселл Холланд Б.В. | Применение дефектного по репликации рекомбинантного аденовируса, содержащего гетерологичную нуклеиновую кислоту, кодирующую антиген cs возбудителя малярии, и белкового антигена, содержащего белок cs или его фрагмент, для лечения или профилактики малярии |
| US20090298955A1 (en) | 2005-02-16 | 2009-12-03 | Konica Minolta Holdings, Inc. | Altered virus capsid protein and use thereof |
| EP3130350A1 (en) | 2005-06-08 | 2017-02-15 | Dana-Farber Cancer Institute, Inc. | Methods and compositions for the treatment of persistent infections and cancer by inhibiting the programmed cell death 1 (pd-1)pathway |
| GB0513421D0 (en) | 2005-06-30 | 2005-08-03 | Glaxosmithkline Biolog Sa | Vaccines |
| CU23586A1 (es) | 2005-11-22 | 2010-10-30 | Ct Ingenieria Genetica Biotech | Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus |
| JP5093097B2 (ja) | 2006-03-03 | 2012-12-05 | 小野薬品工業株式会社 | 細胞表面機能分子の細胞外領域多量体 |
| WO2008025067A1 (en) | 2006-08-30 | 2008-03-06 | Hepgenics Pty Ltd | Recombinant proteins and virus like particles comprising l and s polypeptides of avian hepadnaviridae and methods, nucleic acid constructs, vectors and host cells for producing same |
| CA2705787A1 (en) | 2007-11-26 | 2009-06-25 | Novartis Ag | Methods of generating alphavirus particles |
| CN102317308A (zh) | 2008-11-26 | 2012-01-11 | 美国国有健康与人类服务部 | 类病毒组合物颗粒及其使用方法 |
| PL3067064T3 (pl) * | 2008-12-09 | 2020-11-02 | Novavax, Inc. | Zmodyfikowane białka f rsv i sposoby ich wykorzystania |
| ES2752323T3 (es) | 2009-09-18 | 2020-04-06 | Fraunhofer Usa Inc | Partículas de tipo virus que comprenden proteínas diana fusionadas a proteínas de revestimiento de virus vegetales |
| WO2012006180A1 (en) | 2010-06-29 | 2012-01-12 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Hiv immunogens |
| WO2012023995A1 (en) | 2010-08-18 | 2012-02-23 | Takayuki Shiratsuchi | Modification of recombinant adenovirus capsid protein with immunogenic plasmodium circumsporozoite protein epitopes |
| US9487563B2 (en) | 2011-01-31 | 2016-11-08 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Virus-like particles and methods of use |
| CA2830349C (en) | 2011-03-17 | 2019-07-16 | The University Of Birmingham | Re-directed immunotherapy |
| EP2720715B1 (en) | 2011-06-17 | 2017-08-09 | Bharat Biotech International Limited | Vaccine composition comprising an inactivated chikungunya virus strain |
| CN102321639B (zh) | 2011-09-08 | 2013-06-26 | 中国疾病预防控制中心病毒病预防控制所 | 基孔肯雅病毒病毒样颗粒的制备方法和应用 |
| SG11201401733VA (en) | 2011-10-25 | 2014-09-26 | Florida Gulf Coast University | Vaccines and methods for creating a vaccine for inducing immunity to all dengue virus serotypes |
| WO2013151764A1 (en) | 2012-04-02 | 2013-10-10 | The University Of North Carolina At Chapel Hill | Methods and compositions for dengue virus epitopes |
| LT2850431T (lt) | 2012-05-16 | 2018-06-25 | Immune Design Corp. | Vakcinos, skirtos hsv-2 |
| AU2014275772B2 (en) | 2013-06-03 | 2020-01-02 | Vlp Therapeutics, Inc. | Malaria vaccine |
| US9637532B2 (en) | 2013-07-12 | 2017-05-02 | Vlp Therapeutics, Llc | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen |
| WO2015139784A1 (en) | 2014-03-18 | 2015-09-24 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Distinguishing flavivirus infection using a recombinant mutant envelope protein |
| JP6824154B2 (ja) | 2014-08-08 | 2021-02-03 | ブイエルピー・セラピューティクス・リミテッド・ライアビリティ・カンパニーＶＬＰ Ｔｈｅｒａｐｅｕｔｉｃｓ， ＬＬＣ | 修飾エンベロープタンパク質ｅ３を含むウイルス様粒子 |
| US10385101B2 (en) | 2014-08-08 | 2019-08-20 | Vlp Therapeutics, Llc | Virus like particle comprising modified envelope protein E3 |
| US9363353B1 (en) | 2014-12-04 | 2016-06-07 | Hon Man Ashley Chik | Mobile phone docks with multiple circulating phone connectors |
| SG11201705264WA (en) | 2014-12-31 | 2017-07-28 | The Usa As Represented By The Secretary Detp Of Health And Human Services | Novel multivalent nanoparticle-based vaccines |
| EP3309251A4 (en) | 2015-06-12 | 2019-03-13 | Mie University | HUMAN PARAIN FLUENZA TYPE 2 VIRUS VIRUS VECTOR AND VACCINE |
| WO2016210127A1 (en) | 2015-06-25 | 2016-12-29 | Technovax, Inc. | Flavivirus and alphavirus virus-like particles (vlps) |
| MY187459A (en) | 2015-07-16 | 2021-09-23 | Bharat Biotech Int Ltd | Vaccine compositions |
| EP4218805A1 (en) | 2015-07-21 | 2023-08-02 | ModernaTX, Inc. | Infectious disease vaccines |
| CN106085974B (zh) | 2016-06-07 | 2019-08-09 | 博奥生物集团有限公司 | 一种寨卡病毒假病毒颗粒及其制备方法 |
-
2015
- 2015-08-07 JP JP2017506955A patent/JP6824154B2/ja active Active
- 2015-08-07 EP EP15829311.8A patent/EP3177720B1/en active Active
- 2015-08-07 WO PCT/JP2015/003997 patent/WO2016021209A1/en not_active Ceased
- 2015-08-07 TW TW104125774A patent/TWI720946B/zh active
- 2015-08-07 US US14/820,785 patent/US9969986B2/en active Active
- 2015-08-07 CN CN201580054670.4A patent/CN106795513B/zh active Active
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW201345926A (zh) * | 2012-02-16 | 2013-11-16 | Vlp Therapeutics Llc | 類似病毒粒子組成物 |
Non-Patent Citations (4)
Also Published As
| Publication number | Publication date |
|---|---|
| EP3177720B1 (en) | 2021-09-22 |
| US20160040134A1 (en) | 2016-02-11 |
| JP6824154B2 (ja) | 2021-02-03 |
| WO2016021209A1 (en) | 2016-02-11 |
| CN106795513A (zh) | 2017-05-31 |
| EP3177720A4 (en) | 2018-01-17 |
| EP3177720A1 (en) | 2017-06-14 |
| TW201614067A (en) | 2016-04-16 |
| JP2017523796A (ja) | 2017-08-24 |
| US9969986B2 (en) | 2018-05-15 |
| CN106795513B (zh) | 2021-06-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TWI720946B (zh) | 包含改質套膜蛋白質ｅ３之類病毒粒子 | |
| US10385101B2 (en) | Virus like particle comprising modified envelope protein E3 | |
| US10464986B2 (en) | Virus like particle comprising PD-1 antigen or PD-1 ligand antigen | |
| KR102775741B1 (ko) | Cmv의 변형된 바이러스-유사 입자 | |
| AU2014275772B2 (en) | Malaria vaccine | |
| MX2014009916A (es) | Composicion de particula tipo virus. | |
| CA3121843A1 (en) | Virus-like particles of cmv modified by fusion | |
| CN117222734A (zh) | 靶向半乳凝素的免疫疗法 |